↓ Skip to main content

Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety

Overview of attention for article published in BMC Cancer, November 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety
Published in
BMC Cancer, November 2022
DOI 10.1186/s12885-022-10225-y
Pubmed ID
Authors

K. Sharmni Vishnu, Thin Thin Win, Saint Nway Aye, Arun Kumar Basavaraj

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 18%
Student > Bachelor 2 7%
Other 1 4%
Lecturer > Senior Lecturer 1 4%
Student > Ph. D. Student 1 4%
Other 3 11%
Unknown 15 54%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 3 11%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Medicine and Dentistry 2 7%
Chemical Engineering 1 4%
Agricultural and Biological Sciences 1 4%
Other 3 11%
Unknown 16 57%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2022.
All research outputs
#14,988,291
of 23,056,273 outputs
Outputs from BMC Cancer
#3,712
of 8,371 outputs
Outputs of similar age
#219,936
of 440,155 outputs
Outputs of similar age from BMC Cancer
#56
of 221 outputs
Altmetric has tracked 23,056,273 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,371 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,155 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 221 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.